Retatrutide: Reference Overview and Reconstitution Notes

Retatrutide

What it is

Retatrutide, also identified by the development code LY3437943, is a synthetic peptide (reported as a 39 amino acid sequence) developed by Eli Lilly. It is a single-molecule triple agonist, meaning one molecule activates three receptors at once: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor.

Research context and categorization

Retatrutide is grouped under the metabolic and weight-regulation category. It is commonly discussed in relation to the incretin and glucagon signaling pathways, and it sits in the same broad family as GLP-1 and dual GIP/GLP-1 receptor agonists, extended to add glucagon receptor activity.

In research and clinical-trial settings it has been investigated for body-weight reduction and glycemic (blood-sugar) parameters, and Eli Lilly has described trials studying it in the context of obesity and overweight with a weight-related condition, type 2 diabetes, knee osteoarthritis, obstructive sleep apnea, chronic low back pain, cardiovascular and kidney outcomes, and metabolic dysfunction-associated steatotic liver disease. Because retatrutide is not approved by the FDA or other major regulators, all of these uses are investigational. They are being studied and have not been confirmed or approved, and any figures reported in trials should be read as research findings rather than established benefits.

Status

  • Regulatory status: Research-only and investigational. As of mid-2026 retatrutide is not FDA-approved for any indication and remains in clinical development (Phase 3 trials). It is not available as an approved medicine.
  • Sport status: Prohibited under the WADA Prohibited List. The clearest basis is S0 (non-approved substances), which prohibits at all times any substance not currently approved by a governmental regulatory health authority for human therapeutic use. It is also discussed in relation to the peptide hormones, growth factors, and related substances class (S2) as a peptide-hormone-type agent and, in some analyses, in relation to hormone and metabolic modulators (S4). Athletes should treat it as prohibited.

Reconstitution notes (general)

Retatrutide is supplied as a lyophilized (freeze-dried) powder that is reconstituted before use. Concentration equals the milligrams of powder in the vial divided by the millilitres of bacteriostatic water added. For example, a 10 mg vial reconstituted with 2 mL of bacteriostatic water yields 5 mg/mL. A calculator for working out concentration is linked at our reconstitution and blend calculators.

Dilution and handling notes (compound-specific)

Retatrutide is a lyophilized powder, so it is reconstituted rather than shipped as a ready-to-use liquid. Commonly reported water-per-vial ratios are chosen so that a convenient small measured volume lines up with round numbers on an insulin syringe: for instance roughly 2 mL of bacteriostatic water into a 10 mg vial (5 mg/mL), or about 2 mL into a 20 mg vial (10 mg/mL), with larger vials (for example 40 mg) sometimes taking 2 to 3 mL. Bacteriostatic water, which contains benzyl alcohol as a preservative, is generally preferred over plain sterile water because it supports repeated draws from the same vial across the refrigerated window.

Standard handling is to run the water slowly down the inner wall of the vial rather than squirting it directly onto the powder, then to roll or swirl the vial gently between the fingers instead of shaking. Forceful injection of the diluent and vigorous shaking tend to introduce foam and can stress the peptide. Like other long-acting, fatty-acid-modified peptides in this class, retatrutide may take a short time (often a couple of minutes of gentle rolling) to go fully into solution rather than clearing instantly, and a very dense or compact freeze-dried cake can hydrate slowly and look temporarily clumped or gel-like at first. The practical fix is patience: add the water gently, let it sit, and swirl rather than forcing it. A properly mixed vial should be clear and colorless with no visible particles. Cloudiness, turbidity, a color change, or visible precipitate points to a problem such as aggregation, degradation, a pH or temperature issue, or contamination rather than normal behavior, and the practical response is to discard that vial rather than filter or reheat it. Retatrutide is also light-sensitive in both powder and solution form, so vials are best kept shielded from direct light.

Handling and storage

Store reconstituted material refrigerated at 2 to 8 degrees Celsius and keep it out of light. Wipe the rubber stopper with alcohol before each puncture, and label the vial with the mix date. Observe the general roughly 4-week refrigerated window that is commonly cited for reconstituted solution (reports for retatrutide often note about 28 to 30 days when stored properly). Discard anything that has turned cloudy or discolored or that shows floaters.

Related reading

Tools and supplies

For laboratory and research reference only. Educational content, not medical, dosing, injection, or therapeutic guidance, and not intended for human or animal use. Any research uses described are investigational and not confirmed or approved benefits. Confirm anything involving health with a licensed professional. References linked above.